7dhz › Citations

Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.

Chen S, Wu JL, Liang Y, Tang YG, Song HX, Wu LL, Xing YF, Yan N, Li YT, Wang ZY, Xiao SJ, Lu X, Chen SJ, Lu M
Cancer Cell 39 225-239.e8 (2021)
Cited: 79 times
EuropePMC logo PMID: 33357454

Abstract

TP53 is the most frequently mutated gene in cancer, yet these mutations remain therapeutically non-actionable. Major challenges in drugging p53 mutations include heterogeneous mechanisms of inactivation and the absence of broadly applicable allosteric sites. Here we report the identification of small molecules, including arsenic trioxide (ATO), an established agent in treating acute promyelocytic leukemia, as cysteine-reactive compounds that rescue structural p53 mutations. Crystal structures of arsenic-bound p53 mutants reveal a cryptic allosteric site involving three arsenic-coordinating cysteines within the DNA-binding domain, distal to the zinc-binding site. Arsenic binding stabilizes the DNA-binding loop-sheet-helix motif alongside the overall β-sandwich fold, endowing p53 mutants with thermostability and transcriptional activity. In cellular and mouse xenograft models, ATO reactivates mutant p53 for tumor suppression. Investigation of the 25 most frequent p53 mutations informs patient stratification for clinical exploration. Our results provide a mechanistic basis for repurposing ATO to target p53 mutations for widely applicable yet personalized cancer therapies.

Reviews - 7dhz mentioned but not cited (1)

  1. p53 and Zinc: A Malleable Relationship. Ha JH, Prela O, Carpizo DR, Loh SN. Front Mol Biosci 9 895887 (2022)

Articles - 7dhz mentioned but not cited (5)



Reviews citing this publication (32)

  1. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Nat Rev Gastroenterol Hepatol 20 203-222 (2023)
  2. Drugging p53 in cancer: one protein, many targets. Hassin O, Oren M. Nat Rev Drug Discov 22 127-144 (2023)
  3. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Signal Transduct Target Ther 7 198 (2022)
  4. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, Lei H, Wang J, Xie X, Cheng B, Li Q, Zhang H, Di C. Cell Death Dis 13 974 (2022)
  5. Should mutant TP53 be targeted for cancer therapy? Wang Z, Strasser A, Kelly GL. Cell Death Differ 29 911-920 (2022)
  6. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. Cancer Discov 12 2516-2529 (2022)
  7. The Function of the Mutant p53-R175H in Cancer. Chiang YT, Chien YC, Lin YH, Wu HH, Lee DF, Yu YL. Cancers (Basel) 13 4088 (2021)
  8. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Wang H, Guo M, Wei H, Chen Y. Signal Transduct Target Ther 8 92 (2023)
  9. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Rosell R, Cardona AF, Arrieta O, Aguilar A, Ito M, Pedraz C, Codony-Servat J, Santarpia M. Br J Cancer 125 1602-1611 (2021)
  10. Analysis and Interpretation of the Impact of Missense Variants in Cancer. Petrosino M, Novak L, Pasquo A, Chiaraluce R, Turina P, Capriotti E, Consalvi V. Int J Mol Sci 22 5416 (2021)
  11. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, Wang ES, Wei A, Tallman M. Lancet Haematol 8 e922-e933 (2021)
  12. Clinical and Immunological Effects of p53-Targeting Vaccines. Zhou S, Fan C, Zeng Z, Young KH, Li Y. Front Cell Dev Biol 9 762796 (2021)
  13. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use? Duffy MJ, Tang M, Rajaram S, O'Grady S, Crown J. Cancers (Basel) 14 4499 (2022)
  14. Current strategies and progress for targeting the "undruggable" transcription factors. Zhuang JJ, Liu Q, Wu DL, Tie L. Acta Pharmacol Sin 43 2474-2481 (2022)
  15. GOF Mutant p53 in Cancers: A Therapeutic Challenge. Dolma L, Muller PAJ. Cancers (Basel) 14 5091 (2022)
  16. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Nishikawa S, Iwakuma T. Cancers (Basel) 15 429 (2023)
  17. The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer. Wallis B, Bowman KR, Lu P, Lim CS. Biomolecules 13 159 (2023)
  18. The Development of p53-Targeted Therapies for Human Cancers. Lu Y, Wu M, Xu Y, Yu L. Cancers (Basel) 15 3560 (2023)
  19. The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer. Fregni M, Ciribilli Y, Zawacka-Pankau JE. Int J Mol Sci 23 7213 (2022)
  20. How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes. Loschi M, Fenaux P, Cluzeau T. Cancers (Basel) 14 4519 (2022)
  21. Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome. Pantziarka P, Blagden S. Cancers (Basel) 14 1621 (2022)
  22. Regulation of p53 Function by Formation of Non-Nuclear Heterologous Protein Complexes. Zavileyskiy L, Bunik V. Biomolecules 12 327 (2022)
  23. Small-molecule correctors and stabilizers to target p53. Fallatah MMJ, Law FV, Chow WA, Kaiser P. Trends Pharmacol Sci 44 274-289 (2023)
  24. Targeting mutant p53 stabilization for cancer therapy. Wang J, Liu W, Zhang L, Zhang J. Front Pharmacol 14 1215995 (2023)
  25. Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies. Shen J, Wang Q, Mao Y, Gao W, Duan S. MedComm (2020) 4 e288 (2023)
  26. The crisscross between p53 and metabolism in cancer. Mao Y, Jiang P. Acta Biochim Biophys Sin (Shanghai) 55 914-922 (2023)
  27. TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited. Shin DY. Cancers (Basel) 15 4816 (2023)
  28. Drug Repurposing by Tumor Tissue Editing. Lüke F, Harrer DC, Pantziarka P, Pukrop T, Ghibelli L, Gerner C, Reichle A, Heudobler D. Front Oncol 12 900985 (2022)
  29. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, Xu D, Wang B, Chen D, Ge G. Int J Biol Sci 19 3360-3382 (2023)
  30. Pharmacological reactivation of p53 in the era of precision anticancer medicine. Tuval A, Strandgren C, Heldin A, Palomar-Siles M, Wiman KG. Nat Rev Clin Oncol 21 106-120 (2024)
  31. TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Rahmé R, Braun T, Manfredi JJ, Fenaux P. Biomedicines 11 1152 (2023)
  32. Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma. Li Z, Zhang Z, Fang L, Zhao J, Niu Z, Chen H, Cao G. J Hepatocell Carcinoma 10 2083-2099 (2023)

Articles citing this publication (41)



Quick links